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Abstract
Background LY393558 is a combined antagonist of serotonin (5-HT) 5-HT1B receptors and inhibitor of serotonin transporter 
(SERT). LY393558 reduces 5-HT-induced vasoconstriction and remodelling of rat and/or mouse pulmonary arteries. The aim 
of our study was to examine the effect of LY393558 on the 5-HT-stimulated vasoconstriction of human pulmonary arteries 
(hPAs) and to determine the underlying mechanism(s).
Methods Vascular effects of 5-HT receptor agonists, antagonists and a SERT inhibitor were examined in organ bath studies 
on intralobar hPAs obtained from patients during resection of lung carcinoma.
Results Serotonin and agonists of the 5-HT1B receptor (5-carboxamidotryptamine, 5-CT) and 5-HT2A receptor (α-methyl-
5-HT) contracted endothelium-intact hPAs in a concentration-dependent fashion. The 5-HT1B antagonists SB224289 and 
GR55562 reduced responses induced by 5-HT and 5-CT and the 5-HT2A antagonist ketanserin inhibited the effects of 5-HT 
and α-methyl-5-HT. Administration of the SERT inhibitor citalopram (at a concentration that failed to modify the 5-HT-
induced vasoconstriction) in combination with SB224289 or GR55562 was more effective in inhibiting the response to 5-HT 
than the 5-HT1B antagonists alone. LY393558 showed the greatest antagonistic effect against the vasoconstriction elicited 
by 5-HT, 5-CT and α-methyl-5-HT.
Conclusions LY393558 reduces the 5-HT-induced contraction antagonizing 5-HT1B and 5-HT2A receptors probably due to 
synergic interaction between SERT inhibition and 5-HT1B receptor antagonism. Thus, it might represent a valuable future 
option in the pulmonary arterial hypertension therapy.
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Introduction
Pulmonary arterial hypertension (PAH) is characterized 
by vascular constriction, proliferation, fibrosis and inflam-
mation. The exact pathophysiology of PAH is unknown 
and there is a need for novel therapeutic targets [1–3]. 
The PAH outbreak in people taking anorexigens that are 
indirect serotonergic agonists and may increase serotonin 
(5-hydroxytyramine, 5-HT) plasma levels led to the sero-
tonin hypothesis of this disease. Serotonin induces both a 
vasoconstriction of pulmonary arteries (PAs) mainly via 
5-HT1B and 5-HT2A receptors (5-HT1BRs and 5-HT2ARs) 
and promotes smooth muscle proliferation predominantly 
dependent via the  5HT1BR and the serotonin transporter 
(SERT) [4–6]. The following facts observed in patients 
and/or animal models with PAH confirm the involve-
ment of 5-HT in PAH pathophysiology: (1) higher plasma 
concentration of free 5-HT connected with lower plate-
let 5-HT storage [7]; (2) higher expression of SERT and 
tryptophan hydroxylase 1 (TPH1) than in controls [7]; (3) 
protection or reversal of experimental PAH by genetic 
ablation and/or pharmacological inhibition of TPH1, 
SERT or 5-HT1BRs [1, 2, 8]; (4) mice over-expressing the 
gene for human SERT and SERT knockout mice are more 
and less susceptible to hypoxia-induced PAH, respectively 
[9–11]; (5) greater sensitivity of Fawn-Hooded rats (FH, 
which have a genetic defect in 5-HT platelet storage) than 
Sprague–Dawley (SD) controls to hypoxia-induced PAH 
[12].
Targeting SERT plus 5-HT1BRs may become a novel 
therapeutic approach to PAH [2, 13]. Although SERT 
inhibitors increase 5-HT levels and subsequently lead to 
5-HT receptor activation, synergic activity between SERT 
and 5-HT1BR inhibitors against vasoconstriction and pro-
liferation has been shown in the pulmonary circulation 
[12, 14]. Thus, the combined inhibitory effects of the 
SERT inhibitor fluoxetine (at a concentration that has no 
inhibitory effect of its own) and the 5-HT1BR antagonist 
SB224289 on the 5-HT-induced vasoconstriction of PAs 
isolated from SD were more than additive [12]. LY393558, 
a combined 5-HT1BR antagonist and SERT inhibitor [15, 
16], exerted a more potent effect than SB224289 and fluox-
etine given separately. In addition, it inhibited the 5-HT-
induced constriction of PAs from FH and hypoxic FH and 
SD rats and the proliferation of human pulmonary artery 
smooth muscle cells (hPASMCs) derived from idiopathic 
PAH patients [12, 13]. LY393558 was more effective in 
PAH prevention and reversal in two mouse models of pul-
monary hypertension than the SERT inhibitor citalopram 
[13].
The aim of the present study was to examine the effect 
of LY393558 on the vasoconstriction of human pulmonary 
arteries induced by 5-HT. To determine the effect of 
LY393558 in more detail we extended our experiments 
to 5-HT1BR and 5-HT2AR ligands and the SERT inhibitor 
citalopram.
Materials and methods
Experimental protocols were approved by the Human Ethics 
Committee of the Medical University of Białystok, Poland. 
The tissue donors provided written informed consent for the 
use of their blood vessels.
Lung tissue was received from 29 men and 5 women 
(mean age 65 ± 2  years) with lung carcinoma (without 
PAH) undergoing lobectomy or pneumonectomy. Before 
the operation, they received cephalosporins and heparin as 
anti-infection and antithrombotic prophylaxis, respectively. 
Isolation of hPAs has been described previously [17]. When 
necessary, endothelium was disrupted by rubbing of the 
lumen with horse hair. Arterial rings (3–5 mm in length and 
2–4 mm in outer diameter) were mounted in 10 ml organ 
baths containing Tyrode’s solution [17] gassed with 95% 
 O2 and 5%  CO2 (37 °C, pH 7.4). Resting tension ranged 
from 19.6 to 24.5 mN (equivalent to transmural pressure 
of ~ 16 mmHg). Muscle tension was recorded by a force dis-
placement transducer (BIO-SYS-TECH). After equilibration, 
rings were exposed to high KCl (60 mM) Tyrode’s solu-
tion (equimolar substitution of NaCl by KCl) to check tissue 
viability and maximum contraction and to phenylephrine 
(1 µM) followed by acetylcholine (10 µM) to verify if the 
endothelium is intact. Rings were contracted with 5-HT or 
the agonists 5-CT (5-HT1B/1DR), α-methyl-5-HT (5-HT2AR), 
phenylephrine (α1-adrenoceptor) and U46619 [thromboxane 
 A2 (TP) receptor] and cumulative concentration–response 
curves (CRCs) were constructed. The antagonists GR55562 
(5-HT1B/1DR), SB224289 (5-HT1BR), ketanserin (5-HT2AR), 
the SERT inhibitor citalopram and the combined 5-HT1BR 
antagonist and SERT inhibitor LY393558 were incubated 
for 45 min and also present during construction of CRCs. 
Concentrations of antagonists and citalopram were taken 
from previous studies [4, 5, 12, 13]. In each preparation, 
only one experimental curve was determined.
Citalopram, GR55562, SB224289, U46619, 5-CT, 
α-methyl-5-HT (Tocris); serotonin, ketanserin, (–)-phe-
nylephrine, acetylcholine (Sigma); LY393558 (gift from Eli 
Lilly). Acetylcholine, phenylephrine, citalopram, ketanserin, 
5-CT, GR55562 and SB224289 were dissolved in distilled 
water and 5-HT in distilled water with a few drops of HCl. 
α-Methyl-5-HT was dissolved in water with DMSO, U46619 
in ethanol and water. LY393558 was dissolved in DMSO 
that did not modify CRCs of agonists.
Results are given as mean ± SEM from n patients. Con-
tractile responses were shown as percentages of the response 
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to KCl 60 mM. GraphPad Prism 5.0 software was used to 
plot the mean data as sigmoidal CRCs. CRCs were used 
to determine potency  (pEC50) and maximal effect (Emax) of 
agonists. Antagonist potency  (pA2) was determined accord-
ing to [17].  pEC50 and  pA2 values were not calculated when 
Emax values were < 50%.
Student’s t test for unpaired data was used when one 
experimental group was compared to a control group. 
When ≥ 2 groups were compared to the same control, one-
way analysis of variance (ANOVA) followed by Dunnett’s 
test (post hoc test) was used. Post hoc tests were run only if 
F achieved the necessary level of statistical significance and 
there was no significant variance inhomogeneity. Differences 
were considered significant at p < 0.05.
Results
Contractions (in mN) of 5-HT in endothelium-intact and 
endothelium-denuded hPAs were comparable among the 
groups (Table 1). Basal tension was not affected by 45-min 
pre-incubation with the antagonists, inhibitors and vehicles 
under study (not shown).
Serotonin and agonists of 5-HT1B/1DRs and 5-HT2ARs, 
5-CT and α-methyl-5-HT, respectively, concentration-
dependently contracted endothelium-intact hPAs (Fig. 1a–c). 
The rank order of potencies was 5-CT ≥ 5-HT > α-methyl-
5-HT. The efficacy of 5-CT was lower than that of 5-HT 
and α-methyl-5-HT (F(2,44) = 5.108; p = 0.01; Dunnett’s test: 
p < 0.01 for 5-HT vs. 5-CT; for  pEC50 and Emax see Table 1).
As shown in Fig. 1a, endothelium removal inhibited the 
potency but not efficacy of the 5-HT-mediated contraction 
and caused a threefold rightward shift of its CRC. The SERT 
inhibitor citalopram (1 µM) did not influence the CRC for 
5-HT in endothelium-intact hPAs, but enhanced the potency 
of 5-HT in endothelium-denuded preparations (for  pEC50 
values, see Table 1).
Blockade of 5-HT2ARs by ketanserin (0.1 and 0.01 µM in 
Fig. 1a and c, respectively) shifted the CRC for 5-HT (by a 
factor of 3) and α-methyl-5-HT to the right and diminished 
Emax by 30% (for  pEC50, Emax and  pA2 values see Table 1).
With respect to a putative enhancement of 5-HT1BR 
antagonism by SERT blockade, four scenarios were 
Table 1  Influence of 
antagonists and inhibitors 
on the constriction of human 
pulmonary arteries induced 
by serotonin (5-HT) receptor 
agonists
Data are expressed as mean ± SEM. Contractile responses are given in absolute terms and as percentages of 
the reference response to 60 mM KCl
5-CT 5-carboxamidotryptamine, DMSO dimethyl sulfoxide, -ENDO endothelium removal, N.D. could not 
be determined, n number of patients
*,∆p < 0.05; **,$$p < 0.01; ***,&&&,###p < 0.001, compared to the respective control (*5-HT, $5-HT without 
endothelium, &5-HT (DMSO), ∆5-HT + SB224289 or GR55562, #citalopram + SB224289) as determined 
by one-way ANOVA followed by Dunnett’s post hoc test or aStudent’s t test (for full statistical results, i.e. t, 
df, and p values, see legends and results). Post hoc tests were run only if F achieved the necessary level of 
statistical significance and there was no significant variance inhomogeneity
Group n Tension (mN) pEC50 pA2 Emax
5-HT 28 9.7 ± 1.0 6.20 ± 0.06 94 ± 4
 + Citalopram (1 μM) 11 8.9 ± 1.3 6.45 ± 0.08 87 ± 4
 + SB224289 (0.2 μM) 8 7.0 ± 1.9 5.71 ± 0.07*** 7.02 90 ± 7
 + Citalopram (1 μM)
 + SB224289 (0.2 μM)
12 8.0 ± 1.3 5.58 ± 0.09*** 66 ± 7***,∆,a
 + GR55562 (1 μM) 8 7.2 ± 2.0 5.48 ± 0.11*** 6.63 76 ± 10
 + Citalopram (1 μM)
 + GR55562 (1 μM)
8 7.7 ± 1.2 5.30 ± 0.12*** 51 ± 6***,∆,a
 + Ketanserin (0.1 μM) 4 7.7 ± 1.2 5.66 ± 0.19** 7.40 67 ± 12*
5-HT (-ENDO) 9 9.4 ± 1.2 5.77 ± 0.06*** 92 ± 4
 + Citalopram (1 μM)-ENDO 5 7.6 ± 1.3 6.30 ± 0.15$$,a 90 ± 9
5-HT (DMSO) 9 8.5 ± 1.8 6.34 ± 0.08 82 ± 4
 + LY393558 (0.1 μM) 10 9.1 ± 1.7 5.00 ± 0.12&&&,###,a 8.25 50 ± 5&&&,a
5-CT (DMSO) 12 8.0 ± 1.0 6.36 ± 0.09 73 ± 6
 + SB224289 (0.2 μM) 4 10.0 ± 3.3 5.69 ± 0.27**,a 7.25 52 ± 13
 + GR55562 (1 μM) 6 10.9 ± 1.0 N.D 40 ± 10*
 + LY393558 (0.1 μM) 8 7.3 ± 2.0 N.D 34 ± 9**
α-Methyl-5-HT (DMSO) 7 10.5 ± 1.0 5.89 ± 0.08 79 ± 5
 + ketanserin (0.01 μM) 5 9.7 ± 2.3 N.D 48 ± 11*
 + LY393558 (0.1 μM) 7 10.5 ± 2.4 N.D 26 ± 6***
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considered, including administration of (i) 5-HT1BR 
antagonists (SB224289, GR55562) alone, (ii) citalopram 
alone, (iii) 5-HT1BR antagonists plus citalopram and (iv) 
LY393558 which combines 5-HT1BR antagonism and SERT 
blockade. SB224289 (0.2 µM) and GR55562 (1 µM) caused 
rightward shifts of the CRC for 5-HT by factors of 3 and 5, 
respectively (Fig. 2a) and reduced the efficacy of 5-CT by 
30 and 45%, respectively (Fig. 1b). Citalopram (1 µM) had 
no effect when given alone (see above  pEC50) but when co-
administered with SB224289 (0.2 µM) or GR55562 (1 µM) 
reduced the potency and efficacy of the 5-HT-induced 
contraction (Fig. 2b). In the presence of citalopram, both 
antagonists only tended to diminish the potency of 5-HT 
(t = 1.042, df = 18; p = 0.31; t = 1.106, df = 14; p = 0.287, 
Fig. 1  Influence of endothelium denudation (-ENDO) and/or cit-
alopram (a), ketanserin (a, c), and SB224289, GR55562 (b) and 
LY393558 (b, c) on the vasoconstriction induced by serotonin (5-HT, 
A), 5-carboxamidotryptamine (5-CT, b) and α-methyl-5-HT (c) in 
isolated human pulmonary arteries. Results are expressed as percent-
ages of the contraction induced by KCl and presented as mean ± SEM 
of 4–28 patients for each curve. a Statistical evaluation of the Emax 
values for control, control-ENDO, citalopram and ketanserin yielded 
F(3,48) = 2.580 (p = 0.064) and t = 0.236; df = 12; p = 0.8175 for con-
trol-ENDO vs. citalopram-ENDO. The respective statistical tests 
for the  pEC50 values yielded F(3,48) = 12.86 (p < 0.0001; Dunnett’s 
test: p < 0.01 for ketanserin and for control-ENDO vs. control) and 
t = 3.909; df = 12; p = 0.0021. b Statistical evaluation of the Emax 
values for control, SB224289, GR55562 and LY393558 yielded 
F(3,26) = 5.270 (p = 0.0057; Dunnett’s test: p < 0.05 for GR55562 and 
p < 0.01 for LY393558 vs. control). Comparison of the  pEC50 val-
ues for control and SB224289 yielded t = 3.114; df = 14; p = 0.076. 
c Statistical evaluation of the Emax values for control, ketanserin and 
LY393558 yielded F(2,16) = 15.91 (p = 0.0002; Dunnett’s test: p < 0.05 
for ketanserin and p < 0.001 for LY393558 vs. control)
Fig. 2  Influence of SB224289 and GR55562 (a), of combined 
administration of citalopram plus SB224289 or GR55562 (b) and of 
LY393558 (b) on the vasoconstriction induced by serotonin (5-HT) 
in isolated endothelium-intact human pulmonary arteries. Results are 
expressed as percentages of the contraction induced by KCl and pre-
sented as mean ± SEM of 8–28 patients for each curve. a Statistical 
evaluation of the Emax values for control, SB224289 and GR55562 
yielded F(2,41) = 2.022 ( p = 0.145); the corresponding statistical test 
for the  pEC50 values yielded F(2,41) = 21.98 (p < 0.0001; Dunnett’s 
test: p < 0.001 for both antagonists vs. control). b Statistical evalua-
tion of control, citalopram + SB224289 and citalopram + GR55562 
yielded F(2,45) = 15.930 (p < 0.0001; Dunnett’s test: p < 0.001 for 
both antagonists vs. control) for Emax and F(2,45) = 32.44 (p < 0.0001; 
Dunnett’s test: p < 0.001 for both antagonists vs. control) for  pEC50. 
Statistical testing of control-DMSO vs. LY393558 yielded t = 4.594; 
df = 17; p = 0.0003 for Emax and t = 9.072; df = 17; p < 0.0001 for 
 pEC50
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respectively) but markedly reduced its efficacy (t = 2.324, 
df = 18; p = 0.032; t = 2.144, df = 14; p = 0.050, respec-
tively) when compared to the respective antagonists alone. 
LY393558 (0.1 µM) shifted to the right the CRCs for 5-HT 
(Fig. 2b), 5-CT (Fig. 1b) and α-methyl-5-HT (Fig. 1c) and 
reduced Emax values by 40, 55 and 70%, respectively. The 
antagonistic potency  (pA2) for LY393558 against 5-HT was 
8.3 and higher than that obtained with simultaneous admin-
istration of citalopram and SB224289 (t = 3.939, df = 20; 
p = 0.0008; for  pEC50 and Emax values see Table 1).
LY393558 (0.1 µM) did not modify the vasoconstric-
tory effects on U46619  (pEC50 8.80 ± 0.07, n = 5 vs. con-
trol: 8.60 ± 0.10, n = 6; Emax (relative to the KCl-induced 
response) 105 ± 3% vs. 109 ± 6%) and phenylephrine  (pEC50 
5.50 ± 0.10, n = 6 vs. control: 5.50 ± 0.10, n = 6; Emax 
77 ± 4% vs. 68 ± 5%) (Fig. 3).
Discussion
The aim of the present study was to examine the effect of 
LY393558, a combined 5-HT1BR antagonist and SERT 
inhibitor, on the 5-HT receptor-mediated vasoconstriction 
of hPAs and to determine the underlying mechanism(s).
5-HT induced a concentration-dependent vasoconstric-
tion of endothelium-intact hPAs. The results suggest that 
5-HT1BRs and 5-HT2ARs are involved. First, 5-CT and 
α-methyl-5-HT (5-HT1 and 5-HT2 receptor agonists, respec-
tively) mimicked the vasoconstriction of 5-HT with a rank 
order of potencies of 5-CT ≥ 5-HT > α-methyl-5-HT. 5-CT 
has been shown to be a more potent vasoconstrictor than 
5-HT in main hPAs [4, 13] but they were equipotent in small 
hPAs [5]. Here we show that the efficacy of 5-CT was 20% 
lower than that of 5-HT, whilst other studies have shown 
the efficiency of 5-CT to be 50% less than that of 5-HT 
in hPAs [18]. In contrast to hPAs, responses to 5-HT were 
less in rat [12] and more potent in mouse PAs [13]. Second, 
the 5-HT1BR antagonists SB224289 (has no affinity for the 
SERT; [12]) and GR55562 (5-HT1B/1D-selective antagonist; 
[5]) inhibited the 5-HT-induced vasoconstriction with  pA2 
values of 7.0 and 6.6, respectively, that are consistent with 
their respective values in large hPAs [4] and slightly lower 
than those in small hPAs [5]. Moreover, their inhibitory 
potencies were more potent against the contraction induced 
by the 5-HT1R agonist than that induced by 5-HT. Similarly, 
the 5-HT2AR antagonist ketanserin reduced the response 
to 5-HT with a  pA2 of 7.4 but had a much stronger effect 
against the 5-HT2R agonist.  pA2 values could not be cal-
culated in any case, as described before due to the biphasic 
nature of the 5-HT responses in the presence of ketanserin 
[4, 5].
SERT inhibitors can cause extracellular accumulation 
of 5-HT and subsequent 5-HTR activation and therefore 
potentiate the effects of 5-HT [12, 19]. Indeed the potency 
of 5-HT is reduced in the PAs from  SERT+ mice which 
over-express SERT compared to wild type mice [13] and 
in normoxic SD and FH vessels, and this is associated with 
an enhanced expression of SERT in comparison to their 
hypoxic counterparts [12]. Hence we determined the influ-
ence of SERT inhibition on the 5-HT-induced vasoconstric-
tion. We used citalopram 1 µM as SERT inhibitor (because 
it does not affect 5-HT receptors directly [19]), which, how-
ever, did not change the effect of 5-HT. Our results differ 
from those in intact rat intralobar PAs in which citalopram 
0.1 µM potentiated the 5-HT-induced vasoconstriction [19]. 
Since this effect did not occur in their endothelium-denuded 
counterparts [19], we performed additional experiments in 
endothelium-denuded rings and under these circumstances 
Fig. 3  Influence of LY393558 on the vasoconstriction induced by 
U46619 (a) and phenylephrine (b) in isolated endothelium-intact 
human pulmonary arteries. Results are expressed as percentages 
of the contraction induced by KCl and presented as mean ± SEM of 
5–6 patients for each curve. Statistical evaluation of the Emax val-
ues yielded t = 0.558; df = 9; p = 0.593 for a and t = 1.406; df = 10; 
p = 0.190 for b. The respective statistical tests for the  pEC50 values 
yielded t = 1.571; df = 9; p = 0.150 and t = 0; df = 10; p = 1.0
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citalopram shifted the CRC for 5-HT to the left. The rea-
son why removal of endothelium attenuated the effect of 
5-HT in our hands is unclear. One should keep in mind that 
potentiation, inhibition or lack of effect of citalopram on 
5-HT-induced constriction depends on its concentration, 
vascular bed (pulmonary vs systemic), vessel size, intactness 
of endothelium and oxygen supply (normoxia vs hypoxia) 
[12, 13, 19].
In experiments on endothelium-intact hPAs we observed 
a synergic interaction between SERT inhibition and 
5-HT1BR antagonism. Thus, citalopram at a concentration 
that failed to modify the 5-HT effect in hPAs more strongly 
inhibited the 5-HT-induced vasoconstriction when given 
together with one of the 5-HT1BR antagonists SB224289 or 
GR55562 compared to SB224289 or GR55562 alone. Our 
data conform to previous experiments on PAs from SD rats, 
in which SB224289 exhibited an interaction with an inac-
tive concentration of the SERT inhibitor fluoxetine against 
the 5-HT-induced contraction [12]. The mechanism of this 
interaction is so far not fully understood and may have some-
thing to do with the fact that 5-HT1BRs and SERT appear 
to cooperate in the contractile (and proliferative) effects of 
5-HT in the pulmonary circulation [2].
LY393558 combines 5-HT1BR antagonism and SERT 
inhibition [12, 13, 16] with Ki values of ~ 1 nM in each case 
[15, 16]. We are the first to show that LY393558 strongly 
reduced both potency and efficacy of 5-HT-induced vaso-
constriction in hPAs. Its antagonistic potency was simi-
lar to that of GR55562 plus citalopram and even stronger 
than that of SB224289 plus citalopram. Targeting both 
SERT and 5-HT1BRs is suggested to be a novel therapeutic 
approach to PAH [2, 12]. So far, it has been shown that 
LY393558 strongly reduced the potency and maximal effect 
of the 5-HT-induced constriction of PAs from normoxic and 
hypoxic SD and FH rats (its  pA2 value was not determined 
because Emax values were below 50%); its chronic admin-
istration was more effective in the prevention and reversal 
of PAH in two mouse PAH models than that of citalopram 
[12, 13]. Interestingly, LY393558 reduced the 5-HT-induced 
proliferation of hPASMCs from idiopathic PAH patients 
stimulated by 5-HT [13].
What is the mechanism behind the effect of LY393558 
on the contractile response in hPAs? LY393558 reduced the 
vasoconstriction induced by the 5-HT1R agonist 5-CT to a 
similar extent like GR55562 1 µM and even more strongly 
than SB224289 0.2 µM, confirming its antagonistic activity 
against 5-HT1BRs. Moreover, LY393558 is an antagonist at 
5-HT2ARs  (pKi ~ 100 nM; [16]) and this property appears 
to contribute to the overall effect of LY393558 against the 
5-HT-mediated constriction. Thus, the vasoconstriction 
of hPAs induced by the 5-HT2R agonist α-methyl-5-HT 
was diminished by LY393558 by 50% and by the standard 
5-HT2AR antagonist ketanserin 0.01 µM by 30%.
Although the selectivity of LY393558 for some 5-HT-R 
subtypes has been described [16], to the best of our knowl-
edge no data to its specificity have been published. Our 
data show that the drug does not possess a marked affinity 
at human α1 and TP receptors  (pA2 < 7.0).
Finally, we would like to underline two limitations of 
our study. (1) One may criticize the lack of selectivity 
of 5-HT-R agonists and antagonists. However, according 
to the IUPHAR/BPS Guide to PHARMACOLOGY the 
5-HT2AR agonist α-methyl-5-HT does not possess any 
affinity at 5-HT1BRs and GR55562 is a selective antago-
nist of 5-HT1BRs [20]. Thus, we used at least one selec-
tive agonist or antagonist of 5-HT2ARs and 5-HT1BRs that 
allowed us to conclude that both 5-HT-R subtypes are 
involved in the effect of LY393558. (2) SERT has been 
suggested to play a role in the development of PAH in an 
estrogen-dependent manner both in experimental models 
and in humans [2]. Our experiments were performed in tis-
sues obtained from patients (mainly males) without PAH. 
We cannot exclude that the role of citalopram would be 
more marked in pulmonary arteries isolated from women 
suffering from PAH.
In summary, LY393558 reduced the 5-HT-induced con-
traction antagonizing 5-HT1BRs and 5-HT2ARs and prob-
ably due to synergic interaction between SERT inhibition 
and 5-HT1BR antagonism. Since LY393558 (given acutely 
and/or chronically) has been shown previously to inhibit the 
5-HT-induced hPASMCs proliferation and to prevent and to 
reverse experimental PAH it might represent a future option 
in the PAH therapy.
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